|
[posting]44104333[/posting]Delcath gets boost from German government Enlarge Image Donna Abbott Vlahos | The Business Review Thomas Cosey Jr. examines the bonding of a double-balloon catheter at Delcath’s Queensbury facility. Barbara Pinckney Reporter- The Business Review Delcath Systems Inc. is poised to grow its market in Germany after getting the green light from the country’s federal reimbursement agency. The New York City-based company, which has its manufacturing opertions in Queensbury, Warren County, makes a liver chemotherapy system called Chemostat, and has been setting up delivery channels in Europe for the past year. The decision from the German agency means that while insurers in that country are not mandated to cover Chemostat, hospitals are now permitted to negotiate for coverage. Eamonn Hobbs, president & CEO of Delcath (Nasdaq: DCTH) said this presents a “significant positive step” in the company’s efforts to fully commercialize Chemostat in Europe. “This is the first reimbursement mechanism for our procedure in Germany, the biggest market for CHEMOSAT in the European Union,” he said. “With a direct sales force in place and training of the additional centers in Germany on the way, we are now in a good position to begin growing this market for Chemostat.” Delcath, which last week trimmed its local workforce, earned $146,000 from European sales in the first nine months of 2011—the first product sales in its 24-year history. It is awaiting FDA approval to sell Chemostat in the United States. Pinckney covers banking, health care, media and advertising. |
|
| aus der Diskussion: | Mit Delcath Systems "seperat" die Chemo einsetzen! |
| Autor (Datum des Eintrages): | Magnetfeldfredy (05.02.13 13:51:10) |
| Beitrag: | 33 von 68 (ID:44104817) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |